Robert Wasserman
Stock Analyst at Benchmark
(3.31)
# 938
Out of 4,898 analysts
113
Total ratings
44.44%
Success rate
3.9%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
TECH Bio-Techne | Reiterates: Buy | $75 | $52.62 | +42.53% | 7 | Jun 5, 2025 | |
KMDA Kamada | Reiterates: Buy | $15 | $7.75 | +93.55% | 2 | May 15, 2025 | |
OABI OmniAb | Reiterates: Buy | $6 | $2.06 | +191.97% | 9 | May 12, 2025 | |
ITGR Integer Holdings | Maintains: Buy | $150 → $140 | $119.66 | +17.00% | 11 | Apr 25, 2025 | |
XOMA XOMA Royalty | Initiates: Buy | $35 | $27.55 | +27.04% | 1 | Apr 17, 2025 | |
IPA ImmunoPrecise Antibodies | Reiterates: Speculative Buy | $3 | $1.98 | +51.52% | 6 | Apr 1, 2025 | |
ABCL AbCellera Biologics | Reiterates: Hold | n/a | $4.24 | - | 6 | Mar 3, 2025 | |
HALO Halozyme Therapeutics | Reiterates: Buy | $75 | $57.65 | +30.10% | 9 | Feb 20, 2025 | |
BLFS BioLife Solutions | Reiterates: Buy | $30 | $22.00 | +36.36% | 6 | Dec 19, 2024 | |
ANEB Anebulo Pharmaceuticals | Reiterates: Speculative Buy | $8 | $1.69 | +373.37% | 6 | Nov 19, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $3.70 | +35.30% | 3 | Nov 12, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $7.30 | +64.38% | 17 | Nov 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $3.08 | - | 7 | Nov 4, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $121.33 | - | 3 | Aug 5, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $12 | $0.34 | +3,482.09% | 6 | Jul 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $40.19 | +11.97% | 6 | May 29, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $4.55 | -12.09% | 1 | Mar 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.21 | +1,766.54% | 1 | Mar 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $1.95 | +3,746.15% | 2 | Apr 6, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $197.75 | - | 3 | Oct 24, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $425.34 | +36.36% | 1 | Jul 16, 2021 |
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $52.62
Upside: +42.53%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $7.75
Upside: +93.55%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $2.06
Upside: +191.97%
Integer Holdings
Apr 25, 2025
Maintains: Buy
Price Target: $150 → $140
Current: $119.66
Upside: +17.00%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $27.55
Upside: +27.04%
ImmunoPrecise Antibodies
Apr 1, 2025
Reiterates: Speculative Buy
Price Target: $3
Current: $1.98
Upside: +51.52%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $4.24
Upside: -
Halozyme Therapeutics
Feb 20, 2025
Reiterates: Buy
Price Target: $75
Current: $57.65
Upside: +30.10%
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $22.00
Upside: +36.36%
Anebulo Pharmaceuticals
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $1.69
Upside: +373.37%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $3.70
Upside: +35.30%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $7.30
Upside: +64.38%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $3.08
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $121.33
Upside: -
Jul 11, 2024
Reiterates: Speculative Buy
Price Target: $12
Current: $0.34
Upside: +3,482.09%
May 29, 2024
Reiterates: Buy
Price Target: $45
Current: $40.19
Upside: +11.97%
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $4.55
Upside: -12.09%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.21
Upside: +1,766.54%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $1.95
Upside: +3,746.15%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $197.75
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $425.34
Upside: +36.36%